Early View

Research letter

**BDP/formoterol MART asthma exacerbation benefit increases with blood eosinophil level**

Guy Brusselle, Gabriele Nicolini, Luigi Santoro, Daniele Guastalla, Alberto Papi


This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©The authors 2021. This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.
BDP/formoterol MART asthma exacerbation benefit increases with blood eosinophil level

Authors

Guy Brusselle¹, Gabriele Nicolini², Luigi Santoro², Daniele Guastalla², Alberto Papi³

¹Department of Respiratory Medicine, Ghent University Hospital, Belgium

²Chiesi Farmaceutici SpA, Parma, Italy

³Respiratory Unit, Emergency Department, University of Ferrara, Italy

Corresponding author

Prof. Dr Guy Brusselle

Department of Respiratory Medicine, Ghent University Hospital, C. Heymanslaan 10, B-9000 Ghent, Belgium

guy.brusselle@ugent.be

Take-home message

BDP/FF MART regimen reduced the incidence of severe asthma exacerbations compared with BDP/FF maintenance therapy plus salbutamol as needed across the blood eosinophil continuum, with a trend to a greater reduction in patients with higher baseline counts.
To the editor,

A number of studies have evaluated the effectiveness of a ‘Maintenance And Reliever Therapy’ (MART) regimen combining in a single inhaler the rapid-acting, long-acting β₂-agonist (LABA) formoterol fumarate (FF) with an inhaled corticosteroid (ICS) in asthma [1–5]. Such a regimen is now established for the treatment of moderate-to-severe asthma in adolescents and adults in many guidelines [6, 7]. Furthermore, rescue short-acting β₂-agonists (SABAs) are no longer recommended as sole therapy even for patients with mild asthma, and an ICS/FF combination used as needed is the preferred reliever therapy [6].

A number of studies have examined the impact of a MART regimen on markers of airway inflammation, with discordant findings: In a substudy conducted by Sears et al. a MART regimen had a similar impact on the change from baseline in sputum eosinophil levels to conventional best practice [8], whereas in a study by Pavord et al. MART was less effective in reducing sputum eosinophil levels than high-dose ICS/LABA maintenance treatment, resulting in a significant difference between groups [9]. In contrast in a study by Hozawa et al. a MART regimen was more effective than maintenance ICS/LABA in suppressing airways inflammation [10]. However, these studies did not evaluate the correlation between baseline inflammatory marker levels and the relative efficacy of a MART regimen on clinical outcomes in general, and asthma exacerbations in particular.

Here we therefore investigate whether, in patients with moderate-to-severe asthma, blood eosinophils are theragnostic biomarkers for the relative efficacy of an ICS/FF MART regimen versus maintenance ICS/FF plus rescue SABA. To this aim we performed post-hoc analyses of a randomised controlled trial in patients with uncontrolled asthma, who had been receiving ICS (with or without LABA) for at least two months prior to study entry [3]. The study was 48 weeks in duration, and recruited 1714 adults with asthma who had at least one severe asthma exacerbation in the previous 12 months, pre-bronchodilator forced expiratory volume in 1 second (FEV₁) ≥60% predicted, and whose asthma had been treated regularly with ICS (beclometasone equivalent ≥1000 μg/day) or ICS (beclometasone equivalent ≥500 μg/day).
plus LABA for the previous two months [3]. All patients received maintenance treatment with extrafine beclometasone dipropionate (BDP) 100 μg plus FF 6 μg, one inhalation twice daily via pressurised metered dose inhaler (pMDI), for the duration of the study, including a two-week run-in period. At the end of the run-in period patients whose asthma was not fully controlled (at least one of the following: use of rescue medication more than twice a week; any limitation of activities; any nocturnal symptoms or awakenings; daytime symptoms more than twice a week; or FEV₁ <80% predicted) were randomised equally (1:1) to use as rescue medication either the same extrafine BDP/FF pMDI (i.e., MART regimen) or salbutamol (the BDP/FF+salbutamol group), both one inhalation as needed up to a maximum of six extra inhalations per day. The occurrence of a severe exacerbation was defined as an asthma deterioration resulting in admission to hospital or an emergency department visit, or requiring systemic steroids for at least three days. All patients provided written informed consent prior to any study-related procedure, and the study was registered with ClinicalTrials.gov (NCT00861926). In the overall analyses, the MART regimen significantly increased the time to first severe asthma exacerbation compared with the BDP/FF+salbutamol group, with a 34% reduction in the annualised rate of severe exacerbations (p<0.0001) [3]. For the current post-hoc analyses, the annualised rate of severe exacerbations was compared between the two treatment groups by using a Poisson regression model with number of severe asthma exacerbations as dependent variable, treatment, and country as factors, and with log-time on study as offset. We conducted two sets of analyses. First, patients were grouped by baseline blood eosinophil count into three categories: <150, 150–300 and >300 cells/µL (assessed at the end of the two-week run-in period). The second set of analyses was performed across the blood eosinophil continuum.

When analysed by blood eosinophil category, in the BDP/FF+salbutamol group the percentage of patients with at least one severe exacerbation and the rate of severe exacerbations were both highest in patients with eosinophils >300 cells/µL, but were similar in the other two eosinophil categories (Figure 1a and b). In contrast, in patients receiving the
MART regimen, severe exacerbation percentages and rates were similar in all three eosinophil categories, such that the risk reduction versus BDP/FF+salbutamol was greatest in the >300 cells/µL category (a significant 45.9% risk reduction: rate ratio 0.541 [95% CI 0.397, 0.738]; p<0.001), followed by the 150–300 cells/µL category (a significant 29.5% risk reduction; 0.705 [0.506, 0.983]; p=0.039), although when tested for an interaction between eosinophil count and treatment, the p value was not significant (p=0.191). When analysed across the blood eosinophil continuum, as with the categorical analysis, there was a trend to increasing severe exacerbation rate with increasing eosinophil counts in the BDP/FF+salbutamol group, whereas with the MART regimen the rates were similar regardless of eosinophil count (Figure 1c). Consequently, there was a trend to increasing efficacy with increasing eosinophil levels, although the MART regimen had a greater effect on exacerbations than the BDP/FF+salbutamol group across the entire blood eosinophil continuum (Figure 1d). When the interaction between eosinophil count and treatment was tested across the full continuum (therefore using all information from the data), this approached statistical significance (p=0.083) despite the study being underpowered for this type of analysis. Use of rescue medication was similar in the two treatment groups regardless of eosinophil category (adjusted mean reductions from baseline in reliever use at Week 47–48 of: eosinophils <150 cells/µl, 0.29 and 0.30 inhalations per day; 150–300 cells/µL, 0.25 and 0.25 inhalations per day; ≥300 cells/µL, 0.31 and 0.25 inhalations per day with the MART regimen and BDP/FF+salbutamol, respectively).

The results for the BDP/FF MART regimen in our study are consistent with those of a previous post-hoc analysis of the NovelSTART study, which recruited patients who had been using SABA as sole therapy for asthma, and randomised them to continue salbutamol alone as needed, to receive budesonide/FF (BUD/FF) as needed, or to receive BUD maintenance therapy plus salbutamol as needed [11]. In that post-hoc analysis, patients were grouped by screening blood eosinophil counts in similar categories to those we used (<150, 150–<300 and ≥300 cells/µL): For the group receiving BUD/FF as needed the incidence of severe
exacerbations was similar across blood eosinophil categories [12]. Furthermore, the relative benefit of ICS-based rescue therapy in the two studies (i.e., BDP/FF MART regimen vs BDP/FF+salbutamol in our analyses and BUD/FF as needed vs salbutamol as needed in NovelSTART) increased with increasing blood eosinophil category. The two studies together thus emphasise the importance of ICS-based rescue therapy regardless of background therapy.

Overall, therefore, BDP/FF MART reduced the incidence of severe asthma exacerbations compared with BDP/FF maintenance therapy plus salbutamol as needed across the blood eosinophil continuum and there was a trend to greater reduction of severe exacerbations in patients with higher baseline eosinophil counts.
Acknowledgements and funding

This study was funded by Chiesi Farmaceutici SpA.

The authors would like to thank the investigators and patients at the investigative sites for their support of this study.

Writing support was provided by David Young of Young Medical Communications and Consulting Ltd. This support was funded by Chiesi Farmaceutici SpA.

Conflicts of interest

GB reports honoraria for lectures from AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Teva; he is a member of advisory boards for Amgen, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Sanofi/Regeneron and Teva. All of these declarations are outside the submitted work.

GN, LS and DG are employees of Chiesi, the sponsor of the study.

AP reports payment for advisory board membership, consultancy, and lectures, grants for research, and travel expenses reimbursement from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, and TEVA, payment for advisory board membership, consultancy, and lectures, and travel expenses reimbursement from Mundipharma, Zambon, Novartis, and Sanofi/Regeneron, grants for research, payment for lectures, and travel expenses reimbursement from Menarini, payment for advisory board membership and consultancy, and travel expenses reimbursement from Roche, grants for research from Fondazione Maugeri and Fondazione Chiesi, and payment for consultancy from Edmondpharma, all outside the submitted work.
References

Figure legend

Figure 1. Severe asthma exacerbations: a) Percentage of patients with at least one exacerbation by baseline blood eosinophil category; b) Mean annualised rate and treatment contrasts by baseline blood eosinophil category; c) Mean annualised rate and treatment contrasts across baseline blood eosinophil continuum; d) Adjusted severe exacerbation rate ratio BDP/FF MART regimen vs BDP/FF maintenance plus salbutamol as needed across baseline eosinophil continuum.

BDP, beclometasone dipropionate; FF, formoterol fumarate; MART, Maintenance And Reliever Therapy; RR, risk reduction.